Efficacy and safety of alirocumab in patients with multiple manifestations of cardiovascular disease (CVD): a post-hoc analysis of ODYSSEY program

Back

ESC Premium Access

Efficacy and safety of alirocumab in patients with multiple manifestations of cardiovascular disease (CVD): a post-hoc analysis of ODYSSEY program

Session: Lipids and platelets

Topic: Lipids

Speaker: Professor K. Ray (London, GB)

Event: ESC Congress 2016

Congress Presentation

Add to my library

About the speaker

Professor Kausik K Ray

Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)

91 presentations

16 followers

6 more presentations in this session

Inhibition of lipopolysaccharide induced gene expression by HDL from healthy subjects and patients with acute myocardial infarction

Speaker: Assistant Professor S. Imaizumi (Fukuoka, JP)

Access

Abstract

Association of the postprandial chylomicron triglyceride/apoB index and cardiovascular events

Speaker: Doctor C. Werner (Homburg, DE)

Access

Abstract

Slides

Malondialdehyde assay in evaluation of aspirin antiplatelet effects

Speaker: Mrs L. Dannenberg (Duesseldorf, DE)

Access

Abstract

Slides

C2238 atrial natriuretic peptide molecular variant determines an increased platelet aggregation through the activation of NOX2 and the reduction of cAMP

Speaker: Assistant Professor S. Sciarretta (Rome, IT)

Access

Abstract

Impact of alirocumab on Lp(a) in individuals with and without moderate CKD

Speaker: Professor P. Toth (Baltimore, US)

Access

Abstract

Slides

Access the full session

Lipids and platelets

Speakers: Professor K. Ray, Assistant Professor S. Imaizumi, Doctor C. Werner, Mrs L. Dannenberg, Assistant Professor S. Sciarretta...

Access

About the event

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources